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In previous works, we have shown that insulin-like growth factor-binding protein-3 (IGFBP-3), a tissue and circulating
protein able to bind to IGFs, decreases drastically in the blood serum of patients with diffuse metastatic melanoma. In
agreement with the clinical data, recombinant IGFBP-3 was found to inhibit the motility and invasiveness of cultured
metastatic melanoma cells and to prevent growth of grafted melanomas in mice. The present work was aimed at
identifying the signal transduction pathways underlying the anti-tumoral effects of IGFBP-3. We show that the anti-
tumoral effect of IGFBP-3 is due to inhibition of the Wnt pathway and depends upon the presence of CD44, a receptor
protein known to modulate Wnt signaling. Once it has entered the cell, IGFBP-3 binds the Wnt signalosome interacting
specifically with its component GSK-3b. As a consequence, the b-catenin destruction complex dissociates from the LRP6
Wnt receptor and GSK-3b is activated through dephosphorylation, becoming free to target cytoplasmic b-catenin which
is degraded by the proteasomal pathway. Altogether, the results suggest that IGFBP-3 is a novel and effective inhibitor of
Wnt signaling. As IGFBP-3 is a physiological protein which has no detectable toxic effects either on cultured cells or live
mice, it might qualify as an interesting new therapeutic agent in melanoma, and potentially many other cancers with a
hyperactive Wnt signaling. © 2016 The Authors. Molecular Carcinogenesis Published by Wiley Periodicals, Inc.
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INTRODUCTION
Melanoma is the leading cause of death from skin
diseases due to its propensity to metastasize. In
2010, 114 900 new cases of melanoma were diag-
nosed in the United States for, out of which 68 130
were invasive and resulted in the death of nearly
8700 individuals [1]. Activating mutations of the
proto-oncogene BRAF have been observed in ap-
proximately 50% of malignant melanomas [2].
However, BRAF mutations alone are insufficient to
cause malignant transformation and other trigger-
ing events are needed for melanomagenesis. Since
melanoma is a highly malignant cancer with a
potent capacity to metastasize distantly, an ap-
proach that decreases its metastatic ability may
facilitate the development of an effective strategy for
its treatment and/or prevention. Although the
molecular mechanisms underlying the progression
of melanoma remain unresolved, several studies
have implicated constitutively active Wnt/b-catenin
signaling in melanoma progression and metasta-
sis [3]. Non-phosphorylated b-catenin accumulates
in the cytoplasm; when activated, it enters the
nucleus and interacts with T-cell transcription
factors to control various target genes that are
involved in cellular proliferation and migration.
Nuclear b-catenin accumulation has been correlated
with late stages of tumor progression and metastasis.
The presence of mutated b-catenin is associated with
aggressive tumor growth and regulates expression of
various target genes that mediate cellular processes
including proliferation (e.g., cyclins and c-myc),
migration, and invasion (e.g., matrix metalloprotei-
nases) [3,4]. In the canonical model of Wnt signal-
ing, b-catenin is phosphorylated at certain key
residues by glycogen synthase kinase 3-b (GSK3-b)
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and casein kinase 1a (CK1a), leading to its ubiq-
uitination and subsequent degradation [5,6]. Like
cancers of other organs, the regulation of b-catenin
is lost in melanoma [7–9]. b-catenin is also an
important component of cell–cell adhesion, where it
forms a dynamic link between E-cadherin and
cytoskeleton [10,11]. However, the breaking of
cell-to-cell adhesion due to activation of b-catenin
and its nuclear accumulation may increase the
migration potential of tumor cells. Thus, nuclear/
cytoplasmic traffic of b-catenin in the cells deter-
mines their migration potential [12,13].
The insulin-like growth factor (IGF/IGF-binding
protein) axis has been shown to influence the
proliferation and survival of various tumors [14].
IGFBP-3 is reported to be a growth suppressor by
virtue of its effect on multiple pathways [15].
However, there is also evidence that IGFBP-3 can
have stimulatory effects on the growth of breast
cancer cells [16,17]. In the IGF receptor-
dependent pathways, IGFBP-3 binds to IGF/1-2
and suppresses their growth signal [14]. In the IGF
receptor-independent pathways, IGFBP-3 mediates
a wide variety of growth-controlling signals such as
TGFb, retinoic acid, tumor suppressor protein p53,
vitamin D, anti-estrogens, and tumor necrosis
factor-a [14,17]. Several epidemiological studies
have examined the relationship between the serum
concentrations of IGF/IGFBPs and cancer inci-
dence, emphasizing the evidence that insulin-like
growth factors (IGFs) and insulin-like growth
factor binding proteins (IGFBPs) may represent
specific tumor markers [18–20].
In previous studies, we have shown that a strong
correlation exists between the serum concentration
of IGFBP-3 and disease progression in melanoma
patients [20]. Moreover, a low concentration of
IGFBP-3 was highly significantly correlated with
survival and metastatic volume, indicating that a
dearth of this protein in the blood accompanies, and
perhaps favors, the metastatic dissemination of
melanoma. The anti-migratory and anti-invasive
effect of IGFBP-3 on melanoma cells was confirmed
in vitro, and evidence was also obtained that the
cytokine has anti-tumoral activity in vivo [21]. An
investigation of the cellular pathways involved in
mediating the anti-tumoral action of IGFB-3 indi-
cated Akt and its downstream target GSK3-b as the
kinases predominantly involved. Importantly, we
showed that IGFBP-3 action was independent of
IGF1 and was not mediated by the IGF1 receptor [21].
In this work, we have furthered the investigation of
the cellular pathways affected by IGFBP-3, obtaining
evidence that it acts as an inhibitor of the Wnt
pathway. IGFBP-3 interacts with the b-catenin
destruction complex at the membrane level, thereby
interfering withWnt signaling and causing b-catenin
degradation. A model of IGFBP-3 action on the Wnt
pathway is presented.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
The Wistar primary melanoma (WM793) cell lines
(BRAF V600E; NRAS wt) were kindly provided by Dr.
Meenhard Herlyn, Wistar Institute, Philadelphia, PA.
The cell lines Me501 (BRAF wt; NRAS G10D) were
established from metastases surgically excised from
melanoma patients at the Istituto Nazionale dei
Tumori, Milan, Italy. The LG cell line (BRAF V600E;
NRAS wt) was kindly provided by Dr. Meenhard
Herlyn, Wistar Institute, Philadelphia, PA [21]. The
MCF7 cell line was obtained from ATCC/Wesel,
Germany. All cell lines were seeded in 3-cm Petri
dishes in RPMI 1640 supplemented with 100 IU/mL
penicillin, 100mg/mL streptomycin (Life Technolo-
gies, Gaithersburg, MD), and 2mmol/L glutamine
(Life Technologies) with 10% FCS in a 5% CO2
environment at 378C.
Western Blot and Co-Immunoprecipitation and Reagents
To collect cytosolic, nuclear, and membrane frac-
tions, cells were grown in 60mm dishes and were
lysed. Fractions were collected following the Subcel-
lular protein Fractionation Kit (Thermo Scientific,
Meridian Rd, Rockford, IL) protocol. All the fractions
were incubated with Laemmli sample buffer contain-
ing 5% b-mercaptoethanol at 1008C for 5min before
loading onto the gel. For co-immunoprecipitation of
endogenous protein, Me501 cells were seeded in
100-mm dishes and incubated for the indicated time
points with IGFBP-3. Cells were washed with PBS and
lysed in lysis buffer (20mMTris–HCl, pH 7.4, 150mM
NaCl, 1% NP-40 and mix protease inhibitor) for
15min at 48C. Immunoprecipitation was performed
on lysates with indicated antibody and protein A
Sepharose CL-4B (GE Healthcare, Little Chalfont, UK)
or rabbit-IgG (IgG control, Millipore, Bedford, MA) at
48C over night. The precipitates were washed in lysis
buffer (3) and boiled in SDS-sample buffer contain-
ing b-mercaptoethanol. Samples were subjected
to Western blotting analysis. Antibodies used for
Westerns are as follows: anti-b-catenin, anti-LRP6,
anti-Axin1, anti-Akt (total and phosphor-ser 473),
anti-bTrcp, anti-Gsk3b (S9) (Cell Signaling Techno-
logy, Danvers, MA), anti-IGFBP-3 (Acris, San Diego,
CA), anti-APC (Santa Cruz, Dallas, Texas), anti-E
Cadherin (BD, Franklin Lakes, NJ), anti-Tubulin
(Sigma, Taufkirchen, Germany), anti-Gsk3b and
anti-lamin B1 (Abcam, Cambridge, UK). For IGFBP-3
treatments, recombinant, glycosylated His-tagged
IGFBP-3 was used (Sino Biological, Inc., North Wales,
PA) and, when specified, IGFBP-3 recombinant, non-
glycosylated (MyBioSource San Diego, CA). Wnt
induction was done using recombinant Wnt3a
(200ng/mL: R&D System, Wesbaden, Germany).
The PI3K inhibitor (LY294002) was purchased from
Selleckchem (Munich, Germany). The Akt inhibitor
(Ab142088) was purchased from Abcam.
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Transfection Procedures
siRNA transfection in Me501 or LG cells was
performed using the Lipofectamine LTXPlus transfec-
tion reagent (Invitrogen, Meridian Rd, Rockford, IL)
according to the manufacture’s protocol using 10nM
of CD44 pan siRNA (Santa Cruz).
Immunoelectron Microscopy
Cells samples were fixed for 3h at 48C in a mixture
of 2% paraformaldehyde and 0.1% glutaraldehyde in
0.1M cacodylate buffer, pH 7.6. They were dehy-
drated in alcohol at progressively higher concentra-
tions and embedded in Bioacryl resin (British Biocell,
Cardiff, UK) followed by UV polymerization accord-
ing to standard procedures [22]. Ultrathin sections
were cut and mounted on 300mesh nickel grids. To
block nonspecific binding sites, the grids were treated
with a blocking buffer made of phosphate buffer
saline supplemented with 0.1% Tween-20, 0.1%
bovine serum albumin, and 4% normal goat serum.
For double localization experiments, the grids were
first incubated with anti-IGFBP-3 antibodies 4mg/mL
(Acris) and subsequently with goat anti-rabbit IgG
conjugated with 10nm colloidal gold particles (Brit-
ish Biocell). After washing, the grids were incubated
againwithCD44MouseAb (156-3C11,Cell Signaling)
followed by incubation with goat anti-mouse IgG
conjugated with 20nm colloidal gold particles.
Sections were counterstained in uranyl acetate to
display cell morphology and observed with EM
TECNAI 12 (D1157).
Immunofluorescence Microscopy
Cells were fixed in 4% PBS–paraformaldehyde for
15min, incubated in 0.1% Triton X-100 for 5min on
ice, then in 3% in PBS/BSA for 1h, and stained for 1h
with an anti-b-catenin. DAPI (Invitrogen) was used to
stain nucleic acids (1:1000). The preparations were
examined under a Nikon Eclipse fluorescent micro-
scope equipped with a 20 (0.9NA) and a CCD
camera (Nikon, Inc., Firenze, Italia). Digital images
were processed with Adobe Photoshop 7 software
(Adobe Systems, Mountain View, CA). The level of
b-catenin was quantified and statistically analyzed
using the Student’s t-test.
Scratch-Repair Assay
To evaluate the effect of siRNA CD44 on cell
migration, a scratch-wound assay was done on
Me501 cell. The cells were transfected with control
siRna or siRna against all CD44 isoforms. After the cells
reached confluence (48h), the cell monolayer was
scrapedwith a pipette tip to generate a scratchwound.
The wounded surface was washed with 1 PBS and
incubated in RPMI without fetal bovine serum. Cell
migration into the wound was monitored by phase
microscopy using an Axiovert 200Mmicroscope with
digital camera (Carl Zeiss, Thornwood, NY), taking
pictures after 6h. The images were captured by
AxioVision 4.0 software (Carl Zeiss). The closure of
the initial gap area was assessed by calculating the
difference between the initial and the remaining
wound area. All the experiments were repeated at least
three times.
Statistical Analysis
The Student’s t-test was used for comparison of two
samples. Calculation of the average was performed
usingat least three biological replicates.P-values<0.05
were considered significant. Error bars indicate SD.
RESULTS
IGFBP-3 Treatment Lowers the Cellular Levels of b-Catenin
Previously, we showed that a likely mediator of the
IGFBP-3 anti-migratory and anti-invasive capacity was
the kinase GSK3-b. Since IGFBP-3 treatment of
metastatic melanoma cells up-regulated tyrosinase
and increased the cell’s melanin content [21], we
hypothesized that the cytokine caused the tumor cells
to revert towards a more melanocytic phenotype,
given the known activity of GSK3-b to activate the
transcription of genes involved in melanin synthesis.
GSK3-b, however, is also involved in phosphorylating
key components of the destruction complex that
regulates the cellular levels of b-catenin. As a compo-
nent of the destruction complex (APC/Axin/GSK3)
GSK3-b phosphorylates b-catenin, thus targeting it for
ubiquitination and degradation by the proteasome.
Wnt signaling is assumed to block GSK3-mediated
b-catenin phosphorylation, leading to the accumula-
tion and nuclear translocation of b-catenin [23]. We
decided, therefore, to investigatewhether IGFBP-3had
any effect on the amount of b-catenin in metastatic
melanoma cells.
For this purpose, we began to determine the
abundance of b-catenin and other components of
theWnt/APC/CK1 pathway inmetastatic (Me501 and
LG) and primary (WM793) melanoma cell lines. The
cells were grown to semi-confluence, transferred to a
serum-free medium for 24h, lysed and analyzed. The
cellular levels of the proteins of interest were
determined by Western blotting. As expected (Sup-
plemental Figure S1) the primary melanomas had
APC and Axin 1 levels higher than those of the
metastatic cells; the opposite was true for b-catenin
whichwas abundant in themetastatic lines and below
detection in the primary one. As noted previously, the
kinase Akt was much more active in the metastatic
cells than in primary ones, despite the 24h of
starvation. (Supplemental Figure S1). It should be
stressed that both metastatic cell lines had similar
levels of the markers under study despite their
different genetic backgrounds. The LG cell line had
the same mutational pattern as the primary WM793
cells (BRAF V600E; NRAS wt), while the Me501 cells
were BRAF wt; NRAS G10D. Therefore, the possibility
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that the different pattern of markers of the primary
and the metastatic cells may be due to the different
mutations in the BRAF and NRAS genes can be ruled
out. Accordingly, most of the subsequent experi-
ments were made using the Me501 cells while the LG
cells were used when specified.
To calibrate the experimental system, the meta-
static Me501 cells were preliminarily treated for 2h
with increasing doses of IGFBP-3, using both the
untagged and the His-tagged recombinant cytokine
(Figure 1). The response of the main molecular
markers previously identified [21], Akt (pSer473)
andGSK3-b (pSer9)was checked.As shown inFigure1,
IGFBP-3 caused a marked dephosphorylation of both
target proteins already at the lowest dose (0.2mg/mL).
We note that in most of the assays presented in this
work, we used IGFBP-3 concentrations in the range of
2–5mg/mL, that is, those measured in human blood
serumandused in previous experimentsmade in vitro
and in vivo [21]. Although the tissutal concentrations
of the cytokine must be lower, the results in Figure 1
suggest that the molecular phenotype observed is
most probably not an artefact of IGFBP-3 over-dosage.
Previously [21], we also reported that IGFBP-3 does
not exert any toxic effect on either cultured cells or
live mice, in the latter case even at concentrations ten
times as high as those used in the present work.
The experiments in Figure 1 also demonstrate that
His-tagged anduntagged IGFBP-3were almost equally
effective, discounting the possibility that the presence
of the His-tag may impair the signaling activity of the
cytokine. Accordingly,most of the subsequent experi-
ments were performed with the His-tagged IGFBP-3,
which can be distinguished from the endogenous
species using the appropriate antibodies.
To determine whether treatment with IGFBP-3
affected the cellular levels of b-catenin, WM793,
Me501, and LG cells were exposed to the cytokine for
24h and 48h, and the amount of b-catenin was
checked on whole cell lysates byWestern blotting. As
shown in Figure 2a, treatment with IGFBP-3 drasti-
cally lowered the overall levels of b-catenin in both
metastatic cell lines, while the primary WM793 cells
remained negative for the presence of the protein.
These observations were further checked and verified
by immunofluorescence staining of Me501 cells,
which clearly evidenced the reduced amounts of
b-catenin after treatment with IGFBP-3 for 48h
(Figure 2c).
The analysiswas further refinedby fractionating the
lysates of Me501 cells and measuring the levels of
b-catenin in the different cellular compartments. The
results revealed that both the cytosolic and nuclear
b-catenin fractions were lowered by the IGFBP-3
treatment, while the membrane-bound fraction
remained essentially unchanged (Figure 2b).
IGFBP-3 Decreases b-Catenin Levels via Proteasome
Degradation
Several articles in the literature show that GSK3-b
is able to adjust the levels of b-catenin, by
proteasome dependent degradation [23]. To evalu-
ate whether this was true in our case, the Me501 cells
were treated with IGFBP-3 in the presence or in the
absence of cycloeximide and of the proteasome
inhibitor MG132. As shown in Supplemental
Figure S2a, treatment with IGFBP-3 decreased the
cellular levels of b-catenin both in the absence and
in the presence of cycloeximide. The effect was,
however, reverted by treatment with the proteasome
inhibitor MG132, suggesting that IGFBP-3-induced
b-catenin degradation depends on an active protea-
some pool. This surmise was reinforced by the
finding that treatment with IGFBP-3 for 48h
increased the amount of b-catenin bound to the
b-transducin repeat-containing protein (b-TrCP), a
component of the ubiquitin-ligase complex
targeting b-catenin for proteasomal degradation
b-TrCP [24] (Supplemental Figure S2b).
IGFBP-3 Treatment Increases the Cellular Levels of Axin-1
In resting cells, very low levels of free b-catenin are
present in the cytosol. This pool of b-catenin is
efficiently captured by the destruction complex and
phosphorylated by CKI at Ser45 and by GSK3-b at
Thr41, Ser 37, and Ser33 residues [23].
Axin-1 is the least abundant component and
therefore the rate-limiting factor of the destruction
complex. As such, it can regulate its rapid assembly
and disassembly. Active GSK3-bmay adjust the levels
of Axin-1 by phosphorylation and the phosphory-
lated form of Axin-1 is more stable than the
unphosphorylated form. Therefore, active GSK3-b
phosphorylates bothAxin-1 and b-catenin in the axin
Figure 1. IGFBP-3 effect on Akt and GSK3 phosphorylation. The
metastatic Me501 cells were treated for 2 h with increasing doses of
IGFBP-3, using both the untagged and the His-tagged recombinant
cytokine (0.2–2mg/mL) The phosphorylation levels of Akt (p473) and
GsK3b (pS9) were determined by Western blotting. Statistical
significance was analyzed using the Student's t-test (P< 0.05).
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complex, and these phosphorylations have opposite
effects: the phosphorylation of Axin results in its
stabilization, whereas that of b catenin leads to its
degradation [25].
Accordingly, we tested whether IGFBP-3 treatment
had any effect on Axin-1 stability, and whether this
effect was dependent onGSK3-b inhibition. As shown
in Figure 3a (lanes 1 and 2), treatment of Me501 cells
with LiCl (20mM), a well-established inhibitor of
GSK3-b, caused a marked decrease of cellular Axin-1
and a concomitant increase of b-catenin. The addi-
tion of increasing doses of IGFBP-3 reverted the effect
of LiCl, suggesting reactivation of GSK3-b by this
cytokine. Indeed, as shown in Figure 3b, treatment
with IGFBP-3 in the presence of LiCl caused the
dephosphorylation, hence activation, of GSK3-b
(Ser9).
Importantly, the b-catenin-lowering effect of
IGFBP-3 is not specific of melanoma cells. As shown
in Figure 3c and d, treatment of breast cancer cells
(MCF7)with IGFBP-3 also caused the increase of Axin-
1 and the decrease of b-catenin, indicating that the
same cellular pathways mediate the effect of IGFBP-3
in these cell types.
b-Catenin Downregulation by IGFBP-3 Does Not Depend
on the PI3K Pathway
It is known that a main biological role of IGFBP-3 is
to regulate the PI3K pathway by controlling the
binding of IGF1 to its receptor [17]. In a previous
paper, we showed that the anti-migratory and anti-
invasive effects of IGFBP-3 onmelanoma cells are not
mediated by the IGF1 receptor [21]. To further
exclude the possibility that the effect of IGFBP-3 on
the cellular levels of b-catenin and Axin could be
mediated by the PI3K pathway, we performed the
following experiments.
Me501cells were treated with activators (insulin)
and inhibitors (LY294002) of PI3K, and then the
amounts of b-catenin and the phosphorylation levels
ofAkt andGSK3-bweremeasuredbyWesternblotting.
As expected, insulin treatment increased, and PI3K
inhibitor decreased, the phosphorylation levels of
both Akt and GSK3-b (Supplemental Figure S3).
However, the levels ofb-catenin remainedunaffected,
showing that the PI3Kpathway does not control them
in the Me501 cells. These experiments clearly show
that in our cell lines, the stability of b-catenin does
not dependon the state of phosphorylationofGSK3-b
Figure 2. IGFBP-3 decreases the levels of free, but not membrane-
bound, b-catenin. (a) Me501, LG, and control Wm793 cells were
treatedwith IGFBP-3 (5mg/mL) for 24 and 48h.Whole cell lysates were
prepared, fractionated on gels, and probed with the indicated
antibodies. The lower panel presents a typical Western blot, whereas
the upper one presents a quantification of the data as the mean of
three independent experiments. (b) Membrane, cytosol, and nuclear
fractions were obtain from Me501 cells treated with IGFBP-3 for 24 h
following the Subcellular protein Fractionation Kit (Thermo Scientific)
protocol. The lower panel presents a typical Western blot, whereas the
upper one presents a quantification of the data as the mean of three
independent experiments. (c) Me501 cells were treated with IGFBP-3
(5mg/mL) for 48 h and were then subjected to immunofluorescence
staining using antibodies against b-catenin (green). The nucleus was
stained with DAPI. The right panel presents a quantification of the
data as the mean of three independent experiments. Statistical
significance was analyzed using the Student's t-test (P< 0.05; n.s.,
not significant).
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regulated by PI3K/Akt signal transduction pathway.
In turn, this suggests that IGFBP-3 stimulates the
GSK3-b-induced degradation of b-catenin acting on a
signal transduction pathway different from the PI3K
one.
IGFBP-3 Promotes the Dissociation of GSK3-b From the
LRP6 Wnt Co-Receptor
It is well described in the literature that there are two
differentpoolsofGSK3-bparticipating separately inthe
PI3K/Akt pathway or in the Wnt/Axin pathway [26].
The Axin–GSK3-b complex appears to serve two
functions. First, it allows GSK3-b to target b-catenin
specifically by providing docking sites for both pro-
teins. Second, when GSK3-b is complexed to Axin, it
cannot be targeted by Akt activated by PI3K signaling.
This molecular arrangement allows Wnt and PI3K
inputs to have independent effects on the biological
outputs of the cells that receive these signals [26].
From the above results it can be surmised that
IGFBP-3 may affect b-catenin stability by acting on
the Wnt pathway. To test this hypothesis, we first
verified whether the levels of b-catenin in our cells
were sensitive to the cytokine Wnt. As shown in
Figure 4a, stimulation of theMe501 cells withWnt for
0.5h after 16h of starvation increased the phosphor-
ylation of Akt (Ser473) and GSK3-b (Ser9) and raised
the b-catenin level. IGFBP-3 effectively contrasted the
Wnt-induced Akt and GSK3-b phosphorylation. Note
that in these experiments, the reduction of the
b-catenin levels is barely visible because of the short
time of treatment, while it becomes evident at longer
times. (Figure 4b).
It is known that Wnt treatment activates its co-
receptor LRP6 by phosphorylation at multiple sites
including Thr1479, Ser1490, and Thr1493 by kinases
such as GSK3-b and CK1, resulting in recruitment of
the scaffolding protein Axin to LRP6 and b-catenin
stabilization [27]. This effect is clearly visible on the
Me501 cells following treatment withWnt (Figure 4a,
lane 2). Notably, IGFBP-3, besides reverting the Wnt-
induced phosphorylation of Akt and GSK3-b
(Figure 4a), also caused dephosphorylation of the
LRP6 protein (Figure 4a and b).
The events following the LRP6 receptor activation
are still a subject of debate. However, there is a
consensus thatWnt stimulation promotes the seques-
tration of GSK3-b by binding to the LRP6 receptor,
thus reducing the availability of the cytoplasmic
destruction complex and causing b-catenin
accumulation [27].
With this in mind, we investigated whether IGFBP-
3 affected the interaction of GSK3-b with LRP6. For
this purpose, Me501 cells were treated with IGFBP-3
for 4h, cell lysates were prepared, and the amount of
GSK3-b bound to LRP6 before and after treatment was
Figure 3. IGFBP-3 increases the cellular levels of Axin-1. (a) Me501
cells were treated with LiCl (20mM) and with increasing doses of
IGFBP-3 (2–5 to 10mg/mL) for 8 h. The cell lysates were probed by
Western blot using the indicated antibodies. (b) Me501 cells were
treated with LiCl (20mM) and IGFBP-3 (5mg/mL) for 8 h. The
phosphorylation levels of Akt (p473) and GsK3b (pS9) were
determined by Western blotting. The right panels in (a) and (b)
present a quantification of the data as the mean of three
independent experiments. Statistical significance was analyzed using
the Student's t-test (P< 0.05). (c) Me501 cells were treated with
IGFBP-3 (1.5–3mg/mL) for 48 h and the amounts of b-catenin and
Axin1 were determined by Western blotting with the corresponding
antibodies. (d) Same experiments as in (c) on MCF7 breast cancer
cells (3mg/mL).
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assayed by immunoprecipitationwith anti-total LRP6
antibodies and Western blotting. The results, shown
in Figure 4c, revealed that IGFBP-3 did not affect the
expression levels of LRP6, but did decrease the
amount of GSK, especially of its isoform b, bound
to the LRP6 receptor. These data suggest that IGFBP-3
may promote the disassembly of the destruction
complex from the Wnt receptor, thus enhancing the
availability of GSK3-b in the cytoplasm.
IGFBP-3 Interacts With GSK3-b Below the Plasma
Membrane
To assess the mechanism whereby IGFBP-3 inter-
feres with the Wnt pathway, we hypothesized the
possibility of a direct interaction with the b-catenin
destruction complex. As demonstrated in the litera-
ture, IGFBP-3 is rapidly endocytosed in a complex
with caveolin and clathrin [28]. Indeed, as shown in
Figure 5a, recombinant IGFBP-3 administered to
cultured cells appears in the whole lysates after only
15min. Dephosphorylation of Akt and GSK is also
evident at this time of treatment (see also Figure 1).
To assess the possibility of an interaction with the
destruction complex, we treated the Me501 cells for
0.5 h with IGFBP-3, cell lysates were prepared, and
total IGFBP-3 was immunoprecipitated with the
specific antibody. As shown in Figure 5b, theWestern
blot analysis of the immunoprecipitates evidenced an
Figure 4. IGFBP-3 effects on various components of the Wnt
signalosome. (a) IGFBP-3 inhibits Wnt-induced phosphorylation of
Akt (Ser473) and GSK3-b (Ser9). Me501 cells, deprived of serum for
16 h, were treated with Wnt (200 ng/mL) and IGFBP-3 (2mg/mL) for
0.5 h and the cell lysates were probed with the indicated antibodies
(bottom panel). The results of three independent experiments were
quantified using the ImageJ software, averaged, and plotted (upper
panel). (b) IGFBP-3 induces the dephosphorylation of the Wnt LRP6
receptor. The serum-starved Me501 cells were treated with IGFBP-3
(2mg/mL) for 3 h, lysed, and subjected to Western blot analysis with
the indicated antibodies. Quantification of the data was carried out
as in (a). (c) IGFBP-3 promotes the dissociation of GSK3-b from the
LRP6 receptor. The Me501 cells were treated with IGFBP-3 (2mg/mL)
for 4 h, lysed, and the proteins were immunoprecipitated with the
anti-LRP6 antibody. The precipitated proteins were detected by
Western blotting and quantified as described in (a). Statistical
significance was analyzed using the Student's t-test (P< 0.05; n.s.,
not significant).
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interaction of IGFBP-3 with both GSK3 isoforms. The
results were confirmed by the reciprocal immunopre-
cipitation of IGFBP-3 with the anti-GSK antibodies. In
this case, the precipitates were probed with both anti-
IGFBP-3 and anti-His antibodies to be sure that GSK
indeed interacted with the exogenous IGFBP3
(Figure 5b). In contrast, no interaction was observed
with the Wnt co-receptor LRP6 (not shown).
Since the fraction of GSK3 involved in the Wnt
pathway is that which resides on the membrane, and
IGFBP-3 is associated with GSK3 already after 0.5h of
treatment, we investigated the cellular localization of
IGFBP-3 and of the GSK–IGFBP-3 complex using the
electron microscopy “immunogold” technique.
As shown by the image in Figure 5c, in the control,
IGFBP-3 (smaller dots) and GSK3 (larger dots) are
dispersed over the nucleus and the cytosol, while
already after 0.5 h treatment with IGFBP-3, the two
proteins co-localize just below the plasmamembrane.
After 2h of treatment, IGFBP-3 andGSK3 appear to be
associated inmost of the samples observed (Figure 4c,
last panel). No IGFBP-3 associated with the external
membrane was detected, suggesting that the inter-
nalization of the protein was rapid and efficient.
IGFBP3 Decreases the Phosphorylation at Ser473 of Axin-
Linked Akt
The results presented above demonstrate that
IGFBP-3 interferes with theWnt pathway. Specifically,
the cytokine is able to interact with GSK3-b soon after
entering the cell, causing thedissociationof this kinase
from the b-catenin destruction complex.
However, we have shown previously and in this
work that a prominent early effect of IGFBP-3
treatment on Me501 cells is an almost complete
dephosphorylation of Akt. As shown in Figure 3a, Akt
is phosphorylated at Ser473 upon activation of the
Wnt pathway. Therefore, it is reasonable to assume
that Akt dephosphorylation triggered by IGFBP-3 is
also transduced by the Wnt pathway.
Assessing this point is of particular interest, because
a link between the Wnt pathway and Akt has been
suggested in a few papers but is far from being
demonstrated.
Figure 5. IGFBP-3 interacts with GSK3 under the plasmamembrane.
(a) The Me501 cells were treated for 0.5 h with IGFBP-3 (2mg/mL), cell
lysates were prepared, and the entrance of recombinant IGFBP-3
within the cells at the indicated times was monitored by Western
blotting with an anti-histidine antibody. The phosphorylation state of
Akt (S473) and GSK3-b (S9) was determined with the specific
antibodies (b) The lysates of Me501 cells treated with IGFBP-3
(2mg/mL) for 0.5 hours were immunoprecipitated with anti-IGFBP-3
and GSK3 antibodies and the precipitates were probed with the anti-
GSK3, anti-IGFBP-3, and anti-Histidin antibodies. (c) Representative
ultrathin sections of control Me501 cell samples (left) and samples
treated with IGFBP-3 (5mg/mL) for the indicated times (middle and
right), stained for the immuno-localization of GSK3 (larger dots) and
IGFBP-3 (smaller dots). Specificity controls were negative. The co-
localization of the two proteins in the peripheral zone of the cytoplasm
after IGFBP-3 treatment is clearly visible (black box). The continuous line
shows the plasma membrane (______). Original magnifications:
30.000. Nu, nucleus; Cyt, cytoplasm. Five images from 50 cells
were analyzed and percent co-localization was estimated to be 50 and
95 at 0.5 and 2h, respectively.
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There are a few reports in the literature suggesting
that Akt associateswith theAxin/GSK3 complex upon
Wnt stimulation [29]. We confirmed this observation
by performing an immunoprecipitationwith the anti-
Axin antibody. As shown in Figure 6a, both GSK and
Akt co-immunoprecipitate with Axin in Me501 and
LG cells. The Akt in the destruction complex is
phosphorylated at Ser473. Treatment with IGFBP-3
(2h) does not change the state of association of Akt
with the complex but causes the almost complete
dephosphorylation of Ser473. As suggested in the
literature, the IGFBP-3 induced inactivation of Akt
could in turn induce the dephosphorylation, hence
activation, of GSK [29].
What is the role of Akt in the destruction complex?
It is probably required to maintain in a phosphory-
lated state (hence inactive) GSK3-b, but it could
possibly act on other components of the Wnt
signaling pathway. To learn more about this point,
we treated the Me501 cells with the Akt1/2 inhibitor
for 0.5–1 to 2h and analyzed by Western blot the
phosphorylation state of Akt (Ser473) and LRP6
(Ser1490). The results (Figure 6b) show that Akt
inhibition is able to effectively dephosphorylate the
Wnt co-receptor LRP6 at Ser1490.
Taken together, the above results suggest that, in
melanomacells,Aktboundto thedestructioncomplex
may have a role in transducingWnt-pathway depend-
ing signals, keeping in a phosphorylated state both
GSK and LRP6. IGFBP-3 is apparently able to inactivate
by dephosphorylation the Akt fraction bound to
Axin-1, and this event is probably sufficient to
dephosphorylate the LRP6 receptor and thereby
inhibit the Wnt signaling pathway.
IGFBP3 Acts Through Interaction With CD44
While we were engaged in the study of the effect of
IGFBP-3 on the Wnt pathway in melanoma cells, a
report appeared in the literature indicating that the
protein known as CD44 acts as a positive regulator of
the Wnt receptor complex [30]. CD44 is a transmem-
brane glycoprotein involved in the control of growth,
survival, differentiation, andmotility. Such control is
exerted through interaction with other surface
receptors such as receptor tyrosine kinases (RTKs)
and Wnt [31].
In addition, CD44 is listed as an interactor of
IGFBP-3 in the Human Protein Reference Database
(http://www.hprd.org). Altogether, these reports
prompted us to investigate whether CD44 was
involved in mediating the action of IGFBP-3 on
the Wnt pathway.
To this end, we first analyzed the cellular localiza-
tion of IGFBP-3 and CD44 by the immunogold
electron microscopy technique. The Me501 cells
were treated for 30min with IGFBP-3 and processed
for electron microscopy as described in the Materials
and Methods Section.
Figure 6. IGFBP-3 dephosphorylates Akt on the destruction
complex and the Wnt LRP6 receptor. (a) Lysates of Me501 and LG
cells treated with IGFBP-3 (2mg/mL) for 2 h were immunoprecipitated
with the anti-Axin1 antibody. The indicated proteins were detected
with the appropriated antibodies (bottom panel) and their amounts
were determined using the Image J software (upper panel, averaging
three independent experiments). (b)Western-blotting experiments on
lysates of Me501 cells treated with 20mm Akt inhibitor (Ab142088)
for 0.5–1–2 h. The dephosphorylation of both Akt (S473) and theWnt
LRP6 (S1490) receptor is clearly visible in the treated samples.
Statistical significance was analyzed using the Student's t-test
(P< 0.05).
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As shown in Figure 7a, in untreated cells, IGFBP-3
(white arrow) and CD44 (black arrow) were distrib-
uted between the cytoplasm and the membrane.
However, after treatment with recombinant IGFBP-3,
a co-localization of the two proteins below the
membrane was detected, suggesting that they
may interact in living cells. Interestingly, the co-
localization was clearly observed 0.5h after IGFBP-3
additions, but appeared to be entirely lost after 2h
(not shown). This may indicate that the contact
between CD44 and IGFBP-3 is transient and precedes
the interaction of IGFBP-3 with GSK3 in the destruc-
tion complex. These results are suggestive of a
direct interaction between IGFBP-3 and CD44, but
further data will be required to confirm this
hypothesis.
We then asked whether CD44 was necessary to
mediate the effect of IGFBP-3 on the components of
the Wnt pathway. To this end, we analyzed the
phosphorylation levels of Akt and GSK3 before and
after treatment with IGFBP-3 in Me501 and LG cells
where the expression of CD44 was attenuated by
RNAi.
The results (Figure 7b) revealed that siRNA-
mediated knockdown of CD44 strongly inhibited
IGFBP-3-induced dephosphorylation of Akt and
GSK3 in both cell lines. Note that the efficiency of
siRNA suppression of CD44 expression was some-
what better in LG than inMe501 cells (Supplemental
Figure S4b) but the magnitude of the observed
biological effect was similar in the two lines. Also, it
should be stressed that inhibition of CD44 expres-
sion per se had no effect on any of the molecular
markers analyzed nor affected the amounts of total
Akt or GSK3 (Supplemental Figure S4a, right panel).
Remarkably, the attenuation of CD44 expression by
RNAi had by itself a strong inhibitory effect on the
migratory behavior of Me501 cells (Supplemental
Figure S4a). Taken together, these results suggest that
thepresence ofCD44 is essential tomediate the action
Figure 7. IGFBP-3 requires CD44 to act on the Wnt signalosome. (a)
Electron micrographs showing the co-localization of CD44 (larger gold
particles) and IGFBP-3 (smaller gold particles) after 0.5 h of treatment of
Me501 cells with IGFBP-3 (2mg/mL). Original magnification: 23.000.
Nu, nucleus; Cyt, cytoplasm. (b) Me501 (left panel) and LG cells (right
panel) were transfected with control siRna or siRna against all CD44
isoforms for 48 h. All cells were treated with IGFBP-3 (2mg/mL) for 1 h,
lysed and analyzed byWestern blot for the phosphorylation state of the
indicated proteins. Statistical significance was analyzed using the
Student's t-test (P< 0.05; n.s., not significant) (c) A possible model
depicting the mode of action of IGFBP-3 on the Wnt signalosome.
IGFBP-3 contacts the signalosome by interactingwithCD44, then binds
GSK3-b causing the dephosphorylation of Akt (S473), Gsk3 (S9), and
Lrp6 (S1490) and the dissociation of the destruction complex from the
receptorial complex. The destruction complex becomes activated and
b-catenin is degraded.
690 NASPI ET AL.
Molecular Carcinogenesis
of IGFBP-3 in melanoma and probably other types of
cancer cells.
DISCUSSION
In previous works, we showed that IGFBP-3 is
strongly involved in melanoma progression. A
marked decrease of IGFBP-3 in blood serum was
observed in stage IV melanoma patients, where it
predicts increased metastatic dissemination of the
disease and shorter life expectancy [20]. On the other
hand, treatment with recombinant IGFBP-3 inhibited
melanoma growth in mice and blocked the motility
and invasiveness of cultured melanoma cells [21].
Although the main described role of IGFBP-3 is to
modulate the activity of IGFs, mainly IGF1, the
cytokine also has well-documented IGF1-independent
activities [17]. This turned out to be true also for the
anti-melanoma activity of IGFBP-3. As shown in a
previous work [21], upon treatment ofmelanoma cells
with IGFBP-3, the IGF1-PI3K axis remained inactive,
while themainmediators of the IGFBP-3 anti-tumoral
effect appeared to be AKT andGSK3-b. The underlying
mechanism was not, however, investigated in detail.
In this paper, we have further studied the signal
transduction pathways underlying the anti-tumoral
properties of IGFBP-3 on melanoma cells. Our
findings indicate that IGFBP-3 functions as a modula-
tor of Wnt/b-catenin signaling. The involvement of
IGFBPs in Wnt signaling had been suggested in a few
works by other investigators [32,33] but the possible
mechanism was not dealt with. Here, we show that
IGFBP-3 interacts with certain molecular effectors of
Wnt signaling at the level of the membrane destruc-
tion complex, causing the dissociation thereof from
the Wnt receptor complex and activating b-catenin
degradation.
As shown by our experiments, IGFBP-3 added to the
culturemedium rapidly enters the cells. It is unclear at
this stagewhether IGFBP-3 requires a receptor, possibly
CD44, to be transported inside the cell or whether it
enters independently (presumably via caveolin-
clathrin-dependent endocytosis) and encounters an
internal interactor, which again may be CD44. The
existence of a direct interaction between CD44 and
IGFBP-3 needs further experimental confirmation;
however, CD44 appears to be essential to allow
IGFBP-3 to act on the Wnt signaling machinery.
Indeed, lowering the CD44 concentration by si-RNA
interference strongly reduces IGFBP-3-inducedGSK3-b
and Akt dephosphorylation. Strikingly, a dearth of
CD44 has by itself a potent inhibitory effect on cell
motility, reinforcing the surmise that it is a key player
in regulating the metastatic potential of melanoma
cells.
Among the components of the Wnt signaling
machinery, the principal interactor of IGFBP-3 seems
to be GSK3-b. Treatment with IGFBP-3 causes the
dissociation of GSK3-b (probably alongwith the other
components of the destruction complex) from the
Wnt LRP6 receptor. Concomitantly, GSK3-b becomes
dephosphorylated, hence active, and thereby able to
phosphorylate b-catenin targeting it for destruction.
IGFBP-3 interacts directly with GSK3-b, as shown by
the fact that the two proteins can be immunopreci-
pitated. The primary role of GSK3-b in mediating
IGFBP-3 inhibition of Wnt signaling is also borne out
by the fact that treatment with LiCl, a well-known
inhibitor of GSK3-b, has opposite effects to those
observed upon treatment with IGFBP-3. Treatment
with LiCl increases the phosphorylation of GSK3-b,
decreases the Axin-1 levels, and raises b-catenin ones.
Administration of increasing doses of IGFBP-3 in the
presence of LiCl reverses these Wnt-stimulating
effects of LiCl.
In summary, cells treated with IGFBP-3 have higher
amounts of active destruction complex as demon-
strated by the increased degradation of b-catenin
mediated by b-TrCP.
It is important to point out that PI3K signaling,
although involved in other physiological activities of
IGFBP-3, has nothing to do with the ability of this
cytokine to decrease b-catenin levels. Indeed, treat-
ment of melanoma cells with an inhibitor of PI3K has
no effect at all on the concentration of b-catenin,
albeit reducing the phosphorylation of both Akt and
GSK3-b. This shows that different cellular fractions of
Akt and GSK3-b are involved in PI3K and Wnt
signaling, respectively, and that IGFBP-3 acts on the
latter one.
As we have shown in a previous work and again in
the present one, the earliest effect of IGFBP-3
treatment actually is Akt dephosphorylation. Some
works in the literature implicate Akt in the regula-
tion of the Wnt signaling pathway [29], but its
precise role remains unclear. Here, we show that Akt
phosphorylation at Ser 473 is indeed stimulated
upon Wnt treatment, and that IGFBP-3 is able to
reverse this effect. More importantly, IGFBP-3
specifically causes the dephosphorylation of the
Akt fraction associated with Axin, hence with the
destruction complex. The role of Akt within the Wnt
signalosome warrants more detailed investigations,
but our data indicate that it is probably important to
keep in a phosphorylated state both GSK3-b and the
LRP6 receptor. Indeed, we show that treatment with
an inhibitor of Akt causes the almost complete
dephosphorylation of the LRP6 receptor, indicating
that Akt, in addition to its other multifarious
activities, is also probably pivotal in modulating
Wnt signaling.
In Figure 7c, we present a tentativemodel to explain
the mode of action of IGFBP-3 on Wnt signaling.
IGFBP-3, before or after its entrance in the cell,
interacts (directly or indirectly) with CD44 bound to
the Wnt signalosome. Simultaneously, or in rapid
sequence, IGFBP-3 also interacts with GSK3-b. This
interaction is accompanied by the dissociation of the
Axin destruction complex from theWnt receptor, and
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by the dephosphorylation of Akt first and GSK3-b
immediately afterwards.
Exactly how IGFBP-3 causes Akt and GSK3-b
dephosphorylation is still unclear and will be the
subject of future investigation. Since Akt dephosphor-
ylation precedes that of GSK3-b, it is conceivable that
GSK3-b activation by dephosphorylation is, at least in
part, promoted by the lack of ongoing Akt activity.
The dephosphorylation of the Akt pool linked to the
destruction complex is harder to explain. A possibility
is that the GSK3-b-mediated interaction of IGFBP-3
with the destruction complex increases the activity of
the PP1 phosphatase, known to be associatedwith the
complex. Another possibility would be that the
binding of IGFBP-3 to the destruction complex
somehow hinders the action of the kinase mTorc2,
principally involved in phosphorylating Akt at Ser
473. The two possibilities are not mutually exclusive.
In conclusion, our data show that IGFBP-3 act as a
novel, and strong, inhibitor of Wnt signaling. AsWnt
signaling is involved in a vast series of pathologies,
and pharmaceutical Wnt inhibitors are both scarce
and toxic, recombinant IGFBP-3 might prove to be
useful in the treatment of pathologies related to
perturbations ofWnt signaling, first of all cancer. This
is all the more important since IGFBP-3 is a
physiological protein that showed no adverse effects
when administered in vivo to mice, even at concen-
trations ten times the physiological one in blood
serum [21].
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